High blood pressure, also known as hypertension, is one of the most common health conditions in the world. It affects ...
Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
A study from Columbia University has raised important questions about how doctors treat high blood pressure. The research suggests that one of the most commonly used medicines, called ACE inhibitors, ...
Clinical Trials Arena on MSN
Acerand reports first-in-human trial results for ACE-106 therapy
ACE-106 demonstrated notable anti-tumour activity across different tumour types.
Acerand Therapeutics Reports Promising Clinical Activity and Favorable Safety Profile for ACE-106, a Potential Best-in-Class PARP1 Selective Inhibitor SHANGHAI & INDIANAPOLIS--(BUSINESS WIRE)--Acerand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results